Revumenib + Azacitidine + Venetoclax for Acute Myeloid Leukemia

(RAVEN Trial)

This trial tests a new treatment combination called RAVEN for individuals newly diagnosed with a specific type of acute myeloid leukemia (AML) known as KMT2A-translocated AML. The RAVEN combination includes Revumenib, Azacitidine, and Venetoclax. Researchers aim for this combination to improve outcomes and cause fewer side effects compared to current treatments. The trial consists of two phases: the first phase seeks to put the leukemia into remission, and the second phase continues treatment until certain conditions arise, such as the leukemia returning or receiving a stem cell transplant. Individuals with untreated KMT2A-translocated AML, who have not yet received any treatment, might be suitable candidates for this study. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of participants, offering a chance to contribute to significant advancements in AML treatment.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Research shows that combining revumenib, azacitidine, and venetoclax is generally safe for patients with certain types of acute myeloid leukemia (AML). Studies have found that this treatment can be administered safely and has shown promising results. Specifically, one study reported high rates of complete remission, indicating effective treatment for many patients' leukemia.

Unlike the standard treatments for acute myeloid leukemia (AML), which often include chemotherapy drugs like daunorubicin and cytarabine, this new combination therapy of Revumenib, Azacitidine, and Venetoclax targets the cancer in a unique way. Researchers are excited because Revumenib specifically targets the KMT2A-translocated type of AML, which is a genetic abnormality that makes the leukemia more aggressive and harder to treat. Venetoclax works by inhibiting proteins that help cancer cells survive, while Azacitidine modifies the DNA to stop cancer cell growth. This multi-pronged approach has the potential to be more effective against this challenging form of leukemia, offering hope for better outcomes.

Research has shown that the combination of revumenib, azacitidine, and venetoclax holds promise for treating acute myeloid leukemia (AML) with KMT2A translocation. In one study, 84% of patients achieved remission within the first 28-day treatment cycle, indicating that the treatment can rapidly reduce cancer cells. Patients generally tolerated the combination well, experiencing fewer severe side effects. The study reported an average survival time of 15.5 months, suggesting this treatment may extend life expectancy. Participants in this trial will receive this combination therapy to further evaluate its effectiveness and safety.¹²³⁴⁵